373 related articles for article (PubMed ID: 18308931)
1. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
[TBL] [Abstract][Full Text] [Related]
3. Molecular synergy underlies the co-occurrence patterns and phenotype of
Dovey OM; Cooper JL; Mupo A; Grove CS; Lynn C; Conte N; Andrews RM; Pacharne S; Tzelepis K; Vijayabaskar MS; Green P; Rad R; Arends M; Wright P; Yusa K; Bradley A; Varela I; Vassiliou GS
Blood; 2017 Oct; 130(17):1911-1922. PubMed ID: 28835438
[No Abstract] [Full Text] [Related]
4. MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1.
Kim KT; Carroll AP; Mashkani B; Cairns MJ; Small D; Scott RJ
PLoS One; 2012; 7(9):e44546. PubMed ID: 22970245
[TBL] [Abstract][Full Text] [Related]
5. Cytoplasmic DROSHA and non-canonical mechanisms of MiR-155 biogenesis in FLT3-ITD acute myeloid leukemia.
Nguyen LXT; Zhang B; Hoang DH; Zhao D; Wang H; Wu H; Su YL; Dong H; Rodriguez-Rodriguez S; Armstrong B; Ghoda LY; Perrotti D; Pichiorri F; Chen J; Li L; Kortylewski M; Rockne RC; Kuo YH; Khaled S; Carlesso N; Marcucci G
Leukemia; 2021 Aug; 35(8):2285-2298. PubMed ID: 33589748
[TBL] [Abstract][Full Text] [Related]
6. Regulation of HOX gene expression in AML.
Khan I; Amin MA; Eklund EA; Gartel AL
Blood Cancer J; 2024 Mar; 14(1):42. PubMed ID: 38453907
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
8. C/EBPα and MYB regulate FLT3 expression in AML.
Volpe G; Walton DS; Del Pozzo W; Garcia P; Dassé E; O'Neill LP; Griffiths M; Frampton J; Dumon S
Leukemia; 2013 Jul; 27(7):1487-96. PubMed ID: 23340802
[TBL] [Abstract][Full Text] [Related]
9. XPO1 is a new target of homoharringtonine (HHT): Making NPMc
Xue J; Chu P; Gao W; Wang F; Gao Y; Liu S; Kang Z; Yan J; Wang H
Biochem Biophys Res Commun; 2023 Oct; 675():155-161. PubMed ID: 37473530
[TBL] [Abstract][Full Text] [Related]
10. Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.
Mohr S; Doebele C; Comoglio F; Berg T; Beck J; Bohnenberger H; Alexe G; Corso J; Ströbel P; Wachter A; Beissbarth T; Schnütgen F; Cremer A; Haetscher N; Göllner S; Rouhi A; Palmqvist L; Rieger MA; Schroeder T; Bönig H; Müller-Tidow C; Kuchenbauer F; Schütz E; Green AR; Urlaub H; Stegmaier K; Humphries RK; Serve H; Oellerich T
Cancer Cell; 2017 Apr; 31(4):549-562.e11. PubMed ID: 28399410
[TBL] [Abstract][Full Text] [Related]
11. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
Dawson MA; Gudgin EJ; Horton SJ; Giotopoulos G; Meduri E; Robson S; Cannizzaro E; Osaki H; Wiese M; Putwain S; Fong CY; Grove C; Craig J; Dittmann A; Lugo D; Jeffrey P; Drewes G; Lee K; Bullinger L; Prinjha RK; Kouzarides T; Vassiliou GS; Huntly BJ
Leukemia; 2014 Feb; 28(2):311-20. PubMed ID: 24220271
[TBL] [Abstract][Full Text] [Related]
12. NPM1-Mutated Acute Myeloid Leukemia: Recent Developments and Open Questions.
Patel SS
Pathobiology; 2024; 91(1):18-29. PubMed ID: 36944324
[TBL] [Abstract][Full Text] [Related]
13. Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.
Prokocimer M; Molchadsky A; Rotter V
Blood; 2017 Aug; 130(6):699-712. PubMed ID: 28607134
[TBL] [Abstract][Full Text] [Related]
14. Tumour-derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia.
Peng M; Ren J; Jing Y; Jiang X; Xiao Q; Huang J; Tao Y; Lei L; Wang X; Yang Z; Yang Z; Zhan Q; Lin C; Jin G; Zhang X; Zhang L
J Extracell Vesicles; 2021 Nov; 10(13):e12168. PubMed ID: 34807526
[TBL] [Abstract][Full Text] [Related]
15. Overlapping features of therapy-related and de novo NPM1-mutated AML.
Othman J; Meggendorfer M; Tiacci E; Thiede C; Schlenk R; Dillon R; Stasik S; Venanzi A; Bertoli S; Delabesse E; Dumas PY; Pigneux A; Bidet A; Gilkes AF; Thomas I; Voso MT; Rambaldi A; Brunetti L; Perriello VM; Andresen V; Gjertsen BT; Martelli MP; Récher C; Röllig C; Bornhäuser M; Serve H; Müller-Tidow C; Baldus CD; Haferlach T; Russell N; Falini B
Blood; 2023 Apr; 141(15):1846-1857. PubMed ID: 36508705
[TBL] [Abstract][Full Text] [Related]
16. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.
Gu X; Ebrahem Q; Mahfouz RZ; Hasipek M; Enane F; Radivoyevitch T; Rapin N; Przychodzen B; Hu Z; Balusu R; Cotta CV; Wald D; Argueta C; Landesman Y; Martelli MP; Falini B; Carraway H; Porse BT; Maciejewski J; Jha BK; Saunthararajah Y
J Clin Invest; 2018 Oct; 128(10):4260-4279. PubMed ID: 30015632
[TBL] [Abstract][Full Text] [Related]
17. Demethylator phenotypes in acute myeloid leukemia.
Kelly AD; Madzo J; Madireddi P; Kropf P; Good CR; Jelinek J; Issa JJ
Leukemia; 2018 Oct; 32(10):2178-2188. PubMed ID: 29556023
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
Lim EL; Trinh DL; Ries RE; Wang J; Gerbing RB; Ma Y; Topham J; Hughes M; Pleasance E; Mungall AJ; Moore R; Zhao Y; Aplenc R; Sung L; Kolb EA; Gamis A; Smith M; Gerhard DS; Alonzo TA; Meshinchi S; Marra MA
J Clin Oncol; 2017 Dec; 35(35):3964-3977. PubMed ID: 29068783
[TBL] [Abstract][Full Text] [Related]
19. Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression.
Yun H; Narayan N; Vohra S; Giotopoulos G; Mupo A; Madrigal P; Sasca D; Lara-Astiaso D; Horton SJ; Agrawal-Singh S; Meduri E; Basheer F; Marando L; Gozdecka M; Dovey OM; Castillo-Venzor A; Wang X; Gallipoli P; Müller-Tidow C; Osborne CS; Vassiliou GS; Huntly BJP
Nat Genet; 2021 Oct; 53(10):1443-1455. PubMed ID: 34556857
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients.
Min JW; Koh Y; Kim DY; Kim HL; Han JA; Jung YJ; Yoon SS; Choi SS
Mol Cells; 2018 May; 41(5):465-475. PubMed ID: 29764005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
